



3Q20 M&A Activity

- After historic drops in deal activity, approximately 45% year-to-date, US M&A deal activity responded in the third quarter with over \$400 billion in deal value, an increase of more than 4x quarter-over-quarter, and over 1,000 total transactions, an increase of approximately 22% quarter-over-quarter. There were nearly 3,500 total deals globally, around a 32% decrease compared to the third quarter of 2019. YTD, total deal volumes are nearly 27% lower compared to the same period in 2019 but have strongly rebounded in the third quarter with tepid optimism for the remainder of 2020, given the US election and uncertainties related to COVID.
- On July 21, 2020, Gilead Sciences, Inc. announced that it will invest \$300 million to acquire a 49.9% percent equity interest in Tizona Therapeutics, Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional \$1.25 billion.
- On September 1, 2020, Boston Pharmaceuticals announced an agreement with Novartis through which Boston Pharmaceuticals will license worldwide development and commercial rights to the drug candidate BOS-580, for the treatment of Non-Alcoholic Steatohepatitis (NASH).
- On September 1, 2020, The Bridgewater Group, a premier private investment company that focuses on disrupting industries through innovation announced its subsidiary's purchase of Pfizer's biologics manufacturing facility in Adelaide, Australia. The Adelaide facility has the manufacturing capability, staff expertise, and supporting systems to execute cGMP grade manufacturing and testing of microbial-based products, including proteins, vaccines, and plasmids from development stage through to commercialization.
- On September 21, 2020, Bristol-Myers Squibb Inc. completed the acquisition of clinical-stage protein engineering company Formation Biologics Inc. The targeted company designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases.


Trend in Industry EBITDA Multiples¹



Trends in Revenue Growth and EBITDA Margins¹




Relative Stock Price Returns²



¹ Calculated using aggregated data for JNJ, PFE, Novartis, MRK, ABBV, AMGN, Novo, GSK, Sanofi, LLY, GILD, BMY, LSE:AZN, AGN, MYL, TEVA, BHC, MNK, PRGO, ENDP, AMRX.

² The Pharmaceutical Industry is a custom, equal-weighted index constructed with the aforementioned companies.

Purchase Price Allocation (PPA) % from Recent Transactions



Notable M&A Deals



On August 19, 2020, Johnson & Johnson announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc., a company that discovers and develops novel therapies for immune-mediated diseases, in an all-cash transaction for approximately \$6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases.



On August 17, 2020, Sanofi and Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for \$100 per share in cash, which represents an aggregate equity value of approximately \$3.68 billion (on a fully diluted basis).



On August 6, 2020, Bausch Health Cos. announced it plans to spin off its faster-growing eye-care business from its core pharmaceutical operations, breaking apart a company previous management had built through such acquisitions. The eye-care unit, known as Bausch & Lomb, had \$3.7 billion in revenue last year, compared with about \$4.9 billion from the rest of the company.